Final Overall Survival Confirms Benefit of Durvalumab Plus FLOT in Resectable Gastric and Gastroesophageal Junction Adenocarcinomas

The MATTERHORN trial demonstrated that adding durvalumab, a PD-L1-targeting monoclonal antibody, to the conventional FLOT chemotherapy regimen significantly improves overall survival and event-free survival in patients with resectable gastric and gastroesophageal junction adenocarcinomas. Presented by Dr. Josep Tabernero, the results show consistent benefits across various PD-L1 expression levels and pathologic responses. The study involved 948 patients and is expected to influence treatment standards in localized cases.